Early Detection Research Network

MMP3

Aliases:
This biomarker is also known as:
  • STMY1,
  • Matrix metalloproteinase-3,
  • matrix metallopeptidase 3 (stromelysin 1, progelatinase),
  • SL-1,
  • MGC126104,
  • Stromelysin-1,
  • MGC126102,
  • proteoglycanase,
  • CHDS6,
  • STR1,
  • MMP3,
  • MGC126103,
  • STMY,
  • Transin-1,
  • MMP-3,

Description…

Proteins of the matrix metalloproteinase (MMP) family are involved in the breakdown of extracellular matrix in normal physiological processes, such as embryonic development, reproduction, and tissue remodeling, as well as in disease processes, such as arthritis and metastasis. Most MMP's are secreted as inactive proproteins which are activated when cleaved by extracellular proteinases. MMP3 degrades fibronectin, laminin, collagens III, IV, IX, and X, and cartilage proteoglycans. The enzyme is thought to be involved in wound repair, progression of atherosclerosis, and tumor initiation. The gene is part of a cluster of MMP genes which localize to chromosome 11q22.3.

Datasets

There are no datasets associated with this biomarker.

Attributes
QA State: Curated
Type: Protein
HGNC Name: MMP3

The following organs have data associated with this biomarker…

Attributes

Phase: One
QA State: Curated

Overview

No additional data available.

Performance Comment

Ninety biomarkers were measured using a series of multiplexed immunoassays and results analyzed by the EDRN data management center splitting the cases and controls into training and validation sets, excluding subjects with DCIS or atypical hyperplasia from the training phase. We found little evidence that any of these markers can discriminate women with invasive cancer from those with benign breast conditions.

Attributes

Phase: Three
QA State: Curated

Overview

MMP3 has been shown to be overexpressed in cisplatin-resistant and sensitive ovarian carcinoma cells.

Performance Comment

Of the 28 ovarian cancer biomarkers tested in prediagnostic specimens, from the PLCO, CA125 remains the single best biomarker for ovarian cancer and has its strongest signal within six months of diagnosis. MMP3 alone was not a strong predictor.

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

No associated publications found.